These authors contributed equally to the work.
An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels
Version of Record online: 7 JAN 2013
© 2013 Blackwell Publishing Ltd
British Journal of Haematology
Volume 161, Issue 2, pages 282–286, April 2013
How to Cite
Rösner, T., Derer, S., Kellner, C., Dechant, M., Lohse, S., Vidarsson, G., Peipp, M. and Valerius, T. (2013), An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels. British Journal of Haematology, 161: 282–286. doi: 10.1111/bjh.12209
- Issue online: 3 APR 2013
- Version of Record online: 7 JAN 2013
- Manuscript Accepted: 29 NOV 2012
- Manuscript Received: 27 SEP 2012
- German Research Foundation DFG. Grant Number: 1874/1-1
Fig S1. Biochemical characterization of IgG1 and IgG3 antibodies against CD20.
Fig S2. Functional characterization of IgG1 and IgG3 antibodies against HLA class II.
Fig S3. Functional characterization of monomeric vs. non-fractionated C2B8-IgG3.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.